Business · 04/08/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Patent Extension of BeneFIX
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for BeneFIX, a human biological product, in accordance with the law, following a submission to the Commissioner of Patents and Trademarks for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →